<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235859</url>
  </required_header>
  <id_info>
    <org_study_id>M02-556</org_study_id>
    <nct_id>NCT00235859</nct_id>
  </id_info>
  <brief_title>Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Human Anti-TNF Antibody Adalimumab Administered as Subcutaneous Injections in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and efficacy of adalimumab compared to
      placebo in subjects with rheumatoid arthritis on methotrexate therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR20</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
  </secondary_outcome>
  <enrollment type="Actual">128</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet ACR criteria for diagnosis of active RA and have at &gt;6 swollen joints and &gt;9
             tender joints

          -  Subjects must have received at least one prior DMARD besides MTX, but may have had
             efficacy failures on no more than four standard DMARDs other than MTX

          -  Therapy with MTX for at least 6 months prior to screening and on a stable dose of MTX
             for at least 4 weeks prior to screening visit

          -  Age 18 years and older

        Exclusion Criteria:

          -  Prior treatment with any TNF antagonist, including adalimumab

          -  History of clinically significant drug or alcohol abuse in the previous year, iv drug
             abuse, active infection with listeria or tuberculosis (TB), lymphoma or leukemia,and
             any malignancy with the exception of successfully treated non-metastatic basal-cell
             carcinoma of the skin.

          -  Subjects may not have been administered a live vaccine within three months prior to
             study drug administration or during the study, treatment with any other
             investigational agent within 30 days or 5 half-lives of the agent, whichever is
             longer, prior to the screening evaluation, treatment with any investigational biologic
             agent, including anti-CD4 antibody, within 6 months prior to the screening evaluation,
             prior treatment with any TNF antagonist, including Adalimumab, prior exposure to
             alkylating agents such as chlorambucil or cyclophosphamide.

          -  Chest X-ray with calcified granuloma and/or pleural scarring

          -  Positive TB skin test, RT23 dose skin test, &gt;5 mm at 48 to 72 hours

          -  Unstable ischemic heart disease, active inflammatory bowel disease, active peptic
             ulcer disease, recent stroke (within 3 months of the screening evaluation) or any
             poorly controlled medical condition

          -  Intra-articular, intramuscular or iv administration of corticosteroids within 4 weeks
             prior to screening evaluation

          -  Female who is pregnant or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Paperiello</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2005</study_first_submitted>
  <study_first_submitted_qc>October 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <last_update_submitted>August 28, 2007</last_update_submitted>
  <last_update_submitted_qc>August 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2007</last_update_posted>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

